Riskpilot← Back to searchSign inGet full accessEpista Life Science A/S
A/SActiveCVR 32141064Slotsmarken 17, 2. thComputer consultancy and computer facilities management activities · NACE 6220Est. 200995 employeeswww.epista.com
Revenue 2024
DKK 80,9M
+2% vs 2023
EBITDA margin
2.7%
-79% vs 2023
Equity ratio
17.8%
Financial strength
Net profit 2024
DKK -12,5M
-219% vs 2023
| Revenue | DKK 80,9M | +2% |
| EBITDA | DKK 2,2M | -79% |
| Net profit | DKK -12,5M | -219% |
| Total assets | DKK 165M | +103% |
| Equity | DKK 29,3M | -25% |
| Employees | 95 | — |
Legal name
Epista Life Science A/S
CVR number
32141064
Legal form
Aktieselskab
NACE code
6220 · Computer consultancy and computer facilities management activities
Founded
29. april 2009
Share capital
DKK 529.769
Employees
95 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den administrerende direktør i forening med bestyrelsesformanden eller af den samlede bestyrelse
Company purpose
Selskabets formål er at drive handel og industri.
Address
Slotsmarken 17, 2. th
Phone
+4548254500
Email
info@epista.com
Website
www.epista.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 38.129 | 48.207 | 46.783 | 79.705 | 80.942 |
| Staff expenses | -33.394 | -40.771 | -45.621 | -68.757 | -78.537 |
| EBITDA | 4.735 | 7.436 | 1.163 | 10.755 | 2.220 |
| Depreciation & amort. | -77 | -87 | -87 | -1.127 | -1.629 |
| EBIT | 4.658 | 7.349 | 1.076 | 9.628 | 591 |
| Net financials | 284 | 3.338 | 3.832 | 2.841 | -12.946 |
| Profit before tax | 4.942 | 10.687 | 4.908 | 12.469 | -12.355 |
| Tax | 975 | 1.581 | 185 | 1.972 | 103 |
| Net profit | 3.967 | 9.106 | 4.723 | 10.497 | -12.458 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 24.168 | 25.191 | 54.138 | 81.338 | 164.998 |
| Equity | 8.587 | 14.662 | 28.807 | 39.004 | 29.331 |
| Long-term debt | 2.875 | 0 | 0 | 1.811 | 104.686 |
| Short-term debt | 12.706 | 10.529 | 25.331 | 39.638 | 24.290 |
| Total debt | 15.581 | 10.529 | 25.331 | 41.449 | 128.976 |
EBITDA margin
2.7%
This company
15.8%
Market median
-83% vs market
20202024
Equity ratio
17.8%
This company
38.2%
Market median
-53% vs market
20202024
Return on equity
-42.5%
This company
18.4%
Market median
-331% vs market
20202024
Net profit margin
-15.4%
This company
8.1%
Market median
-290% vs market
20202024
Asset turnover
0.49×
This company
1.12×
Market median
-56% vs market
20202024
Debt / equity
4.63×
This company
0.62×
Market median
-647% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
PE Chief Executive Officer | Chief Executive Officer | 2026 |
| Former (1) | ||
MW Management | Management | 2009 – 2012 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2016 | |
| Board of Directors | 2022 | |
| Chairman | 2026 | |
| Board of Directors | 2013 | |
| Former (4) | ||
| Chairman | 2013 – 2016 | |
| Chairman | 2022 – 2025 | |
| Chairman | 2025 – 2026 | |
| Board of Directors | 2013 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2024 | |
| Individual | 5–9.99% | 5–9.99% | 2014 | |
| Individual | 5–9.99% | 5–9.99% | 2014 | |
| Company | 66.67–89.99% | 66.67–89.99% | 2021 | |
| Company | 10–14.99% | 10–14.99% | 2021 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
LYKKE BANK HOLDING ApS
Epista Life Science A/S Board members of Epista Life Science A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Martin Woergaard | Management | 0 companies |
| Per Erik Mikael Johansson | Chief Executive Officer | 0 companies |
| Knut Ronny Christer Roos | Board of Directors | 0 companies |
| Katarína Larsen | Board of Directors | 0 companies |
| Mette Pilmann Esbjerg | Chairman | 0 companies |
| Line Hyldgaard Hjorth-Christensen | Chairman | 0 companies |
| Maximilian Weimann | Chairman | 0 companies |
| Simon Carl Vilhelm Larsson | Chairman | 0 companies |
| Klavs Esbjerg | Board of Directors | 0 companies |
| Ken Rasmussen | Board of Directors | 0 companies |